Sarah Davis

MPhys

School of Health and Related Research

Senior Lecturer in Health Economics

s.davis@sheffield.ac.uk
+44 114 222 5209

Full contact details

Sarah Davis
School of Health and Related Research
1011
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Profile

I have over 15 years experience in developing health economic models to evaluate the cost-effectiveness of healthcare interventions including diagnostic tests, risk-assessment tools, and both pharmacological and non-pharmacological treatments. I work primarily on NICE technology appraisals and research projects funded by the NIHR HTA programme. I am a member of ScHARR-TAG and I was the Deputy Director of the NICE Decision Support Unit (DSU) from January 2010 to March 2022

I previously spent three years as the Senior Health Economist at the National Collaborating Centre for Nursing and Supportive Care which developed Clinical Guidelines for NICE. When this centre was merged with three others to form the National Clinical Guideline Centre (NCGC) in April 2009, I joined the NCGC as Health Economics Lead. Prior to this, I was a cost-effectiveness modeller within the HEDS section at ScHARR from 2004 to 2006.

Research interests

My research interests are cost-effectiveness modelling, technology appraisal, and clinical guideline development.

Current projects

  • The cost-effectiveness of venous thromboembolism risk assessment tools for hospital inpatients - NIHR127454
Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Conference proceedings papers

  • Mattia L, Mark-Wagstaff C, Abrahamsen B, Davis S, Peel N, Eastell R & Schini M (2022) Monitoring Bisphosphonate Treatment In Primary Care: PINP And Osteoporosis In Sheffield Evaluation (POSE Study). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 64-65) RIS download Bibtex download
  • Clark E, Khera T, Hunt L, Gooberman-Hill R, Paskins Z, Peters T, Tobias J & Davis S (2022) Addition of symptoms to traditional risk factors improves prediction of those at high risk of vertebral fractures: Results of the Vfrac study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 60-60) RIS download Bibtex download
  • Bastounis A, Langley T, Davis S, Paskins Z, Gittoes N, Leonardi-Bee J & Sahota O (2021) ASSESSING THE EFFECTIVENESS OF BISPHOSPHONATES FOR THE PREVENTION OF FRAGILITY FRACTURES: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSES. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S270-S270) RIS download Bibtex download
  • Mattia L, Mark-Wagstaff C, Abrahamsen B, Davis S, Peel N, Eastell R & Schini M (2021) MONITORING BISPHOSPHONATE TREATMENT IN PRIMARY CARE: PINP AND OSTEOPOROSIS IN SHEFFIELD EVALUATION (POSE STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S288-S288) RIS download Bibtex download
  • Elphick H, Horspool M, Davis S, Bradburn M, Norman P, Shephard N, Cooper C, Smithson WH, Boote J, Loban A , Franklin M et al (2016) LATE-BREAKING ABSTRACT: PLEASANT: Preventing and lessening exacerbations of asthma in school-age children associated with a new term. 1.6 General Practice and Primary Care RIS download Bibtex download
  • Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad E, Buyse M & Taylor R (2013) VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMOURS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. VALUE IN HEALTH, Vol. 16(7) (pp A327-A327) RIS download Bibtex download
  • Brennan A, Wilson R, Davis S, Brandtmuller A & Akehurst R (2007) Economic evaluation of the use of lanthanum carbonate from an Australian perspective. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 22 (pp 186-186) RIS download Bibtex download
  • Brennan A, Akehurst R, Davis S & Sakai H (2004) Lanthanum carbonate for the treatment of hyperphosphataemia: Development of a cost effectiveness model. VALUE HEALTH, Vol. 7(6) (pp 805-805) RIS download Bibtex download

Reports

Teaching interests

My teaching interests include decision modelling in health care and supporting non-health economists to engage with health economic evidence when developing guidance for the NHS.

Professional activities

Member of NICE Highly Specialised Technologies Evaluation Committee